Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2014

01-07-2014 | Preclinical study

Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers

Authors: Tarek Abdel-Fatah, Arvind Arora, Devika Agarwal, Paul Moseley, Christina Perry, Nicola Thompson, Andrew R. Green, Emad Rakha, Stephen Chan, Graham Ball, Ian O. Ellis, Srinivasan Madhusudan

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Abstract

DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine threonine kinase belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is a critical component of the non-homologous end-joining pathway required for the repair of DNA double-strand breaks. DNA-PKcs may be involved in breast cancer pathogenesis. We evaluated clinicopathological significance of DNA-PKcs protein expression in 1,161 tumours and DNA-PKcs mRNA expression in 1,950 tumours. We correlated DNA-PKcs to markers of aggressive phenotypes, DNA repair, apoptosis, cell cycle regulation and survival. Low DNA-PKcs protein expression was associated with higher tumour grade, higher mitotic index, tumour de-differentiation and tumour type (ps < 0.05). The absence of BRCA1, low XRCC1, low SMUG1, low APE1 and low Polβ was also more likely in low DNA-PKcs expressing tumours (ps < 0.05). Low DNA-PKcs protein expression was significantly associated with worse breast cancer-specific survival (BCSS) in univariate and multivariate analysis (ps < 0.01). At the mRNA level, similarly, low DNA-PKcs was associated with poor BCSS. In patients with ER-positive tumours who received endocrine therapy, low DNA-PKcs (protein and mRNA) was associated with poor survival. In ER-negative patients, low DNA-PKcs mRNA remains significantly associated with adverse outcome. Our study suggests that low DNA-PKcs expression may have prognostic and predictive significance in breast cancers.
Appendix
Available only for authorised users
Literature
3.
go back to reference Hill R, Lee PW (2010) The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle 9(17):3460–3469PubMedCrossRef Hill R, Lee PW (2010) The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle 9(17):3460–3469PubMedCrossRef
9.
10.
go back to reference Hu Z, Liu H, Wang H, Miao R, Sun W, Jin G et al (2008) Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage “checkpoints” and lung cancer susceptibility. Clin Cancer Res 14(9):2887–2891. doi:10.1158/1078-0432.CCR-07-1822 PubMedCrossRef Hu Z, Liu H, Wang H, Miao R, Sun W, Jin G et al (2008) Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage “checkpoints” and lung cancer susceptibility. Clin Cancer Res 14(9):2887–2891. doi:10.​1158/​1078-0432.​CCR-07-1822 PubMedCrossRef
16.
17.
go back to reference Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C et al (2014) DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol 8(3):520–532. doi:10.1016/j.molonc.2014.01.001 PubMedCrossRef Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C et al (2014) DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol 8(3):520–532. doi:10.​1016/​j.​molonc.​2014.​01.​001 PubMedCrossRef
18.
go back to reference Abdel-Fatah TM, Perry C, Moseley P, Johnson K, Arora A, Chan S et al (2014) Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res Treat 143(3):411–421. doi:10.1007/s10549-013-2820-7 PubMedCrossRef Abdel-Fatah TM, Perry C, Moseley P, Johnson K, Arora A, Chan S et al (2014) Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res Treat 143(3):411–421. doi:10.​1007/​s10549-013-2820-7 PubMedCrossRef
19.
go back to reference Abdel-Fatah TM, Albarakati N, Bowell L, Agarwal D, Moseley P, Hawkes C et al (2013) Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res Treat 142(3):515–527. doi:10.1007/s10549-013-2769-6 PubMedCrossRef Abdel-Fatah TM, Albarakati N, Bowell L, Agarwal D, Moseley P, Hawkes C et al (2013) Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res Treat 142(3):515–527. doi:10.​1007/​s10549-013-2769-6 PubMedCrossRef
20.
go back to reference Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984 PubMedCrossRef Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.​1200/​JCO.​2013.​50.​9984 PubMedCrossRef
22.
go back to reference Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352PubMedCentralPubMed Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352PubMedCentralPubMed
26.
go back to reference Lee HS, Choe G, Park KU, Park do J, Yang HK, Lee BL et al (2007) Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol 31(4):859–866PubMed Lee HS, Choe G, Park KU, Park do J, Yang HK, Lee BL et al (2007) Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol 31(4):859–866PubMed
29.
go back to reference Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX (2007) Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance. Zhonghua zhong liu za zhi (Chin J Oncol) 29(9):697–700 Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX (2007) Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance. Zhonghua zhong liu za zhi (Chin J Oncol) 29(9):697–700
30.
go back to reference Soderlund Leifler K, Queseth S, Fornander T, Askmalm MS (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37(6):1547–1554PubMed Soderlund Leifler K, Queseth S, Fornander T, Askmalm MS (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37(6):1547–1554PubMed
Metadata
Title
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers
Authors
Tarek Abdel-Fatah
Arvind Arora
Devika Agarwal
Paul Moseley
Christina Perry
Nicola Thompson
Andrew R. Green
Emad Rakha
Stephen Chan
Graham Ball
Ian O. Ellis
Srinivasan Madhusudan
Publication date
01-07-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3035-2

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine